These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16515882)

  • 21. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
    de Man RA; Wolters LM; Nevens F; Chua D; Sherman M; Lai CL; Gadano A; Lee Y; Mazzotta F; Thomas N; DeHertogh D
    Hepatology; 2001 Sep; 34(3):578-82. PubMed ID: 11526545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of chronic hepatitis B].
    Marcellin P; Asselah T; Boyer N
    Rev Prat; 2005 Mar; 55(6):624-32. PubMed ID: 15913114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].
    Ma H; Ren JB; Li HY; Wang Y; Wang RL; Liang L; Sun SJ; Jia JD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):102-4. PubMed ID: 17653304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Entecavir for the long-term treatment of chronic hepatitis B.
    Gonzalez SA; Keeffe EB
    Expert Rev Anti Infect Ther; 2009 Nov; 7(9):1053-62. PubMed ID: 19883325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Entecavir--close perspective for using it].
    Halota W; Pawłowska M
    Przegl Epidemiol; 2006; 60(1):115-8. PubMed ID: 16758749
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
    Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
    Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis B: preventing, detecting, and managing viral resistance.
    Keeffe EB; Dieterich DT; Pawlotsky JM; Benhamou Y
    Clin Gastroenterol Hepatol; 2008 Mar; 6(3):268-74. PubMed ID: 18328434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic hepatitis B.
    Mohanty SR; Kupfer SS; Khiani V
    Nat Clin Pract Gastroenterol Hepatol; 2006 Aug; 3(8):446-58. PubMed ID: 16883349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [A study of the dosage and efficacy of entecavir for treating hepatitis B virus].
    Yao GB; Zhang DF; Wang BE; Xu DZ; Zhou XQ; Lei BJ
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):484-7. PubMed ID: 16042878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
    Xu XW; Chen YG
    Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
    J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic hepatitis B.
    Marcellin P; Asselah T; Boyer N
    J Viral Hepat; 2005 Jul; 12(4):333-45. PubMed ID: 15985003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
    Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiviral therapy for hepatitis B virus associated hepatic failure.
    Wang YM; Tang YZ
    Hepatobiliary Pancreat Dis Int; 2009 Feb; 8(1):17-24. PubMed ID: 19208509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Entecavir is a potent anti-HBV drug superior to lamivudine: experience from clinical trials in China.
    Yao G
    J Antimicrob Chemother; 2007 Aug; 60(2):201-5. PubMed ID: 17556353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapy of chronic hepatitis B: trends and developments.
    Delaney WE; Borroto-Esoda K
    Curr Opin Pharmacol; 2008 Oct; 8(5):532-40. PubMed ID: 18835366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B].
    Calcagno JI; Augustovski F; Gadano A; Souto A; Yuan Y
    Acta Gastroenterol Latinoam; 2008 Dec; 38(4):260-73. PubMed ID: 19157381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: Nucleoside analogues for the treatment of chronic hepatitis B.
    Younger HM; Bathgate AJ; Hayes PC
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1211-30. PubMed ID: 15606384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current treatment of chronic hepatitis B: benefits and limitations.
    Perrillo RP
    Semin Liver Dis; 2005; 25 Suppl 1():20-8. PubMed ID: 16103978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2011; 65(2):313-7. PubMed ID: 21913482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.